Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Moderna ( (MRNA) ) just unveiled an update.

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This ...

Moderna's chief technical operations officer explains why now is the right time to take full control of the company's ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderately bullish activity in Moderna (MRNA), with shares up 62c, or 2.55%, near $24.77. Options volume relatively light with 58k contracts ...

An audit of the federal government’s controversial deal to bring Moderna to Melbourne to manufacture vaccines has been ...